Fondaparinux Sodium: Recent Advances in the Management of Thrombosis.
J Cardiovasc Pharmacol Ther
; 28: 10742484221145010, 2023.
Article
Dans Anglais
| MEDLINE | ID: covidwho-20233025
ABSTRACT
Fondaparinux sodium is a chemically synthesized selective factor Xa inhibitor approved for the prevention and treatment of venous thromboembolic events, that is, deep vein thrombosis, pulmonary embolism, and superficial vein thrombosis, in acutely ill (including those affected by COVID-19 or cancer patients) and those undergoing surgeries. Since its approval in 2002, the efficacy and safety of fondaparinux is well demonstrated by many clinical studies, establishing the value of fondaparinux in clinical practice. Some of the advantages with fondaparinux are its chemical nature of synthesis, minimal risk of contamination, 100% absolute bioavailability subcutaneously, instant onset of action, a long half-life, direct renal excretion, fewer adverse reactions when compared with direct oral anticoagulants, and being an ideal alternative in conditions where oral anticoagulants are not approved for use or in patients intolerant to low molecular weight heparins (LMWH). In the last decade, the real-world use of fondaparinux has been explored in other conditions such as acute coronary syndromes, bariatric surgery, in patients developing vaccine-induced immune thrombotic thrombocytopenia (VITT) and in pregnant women with heparin-induced thrombocytopenia (HIT), or those intolerant to LMWH. The emerging data from these studies have culminated in recent updates in the guidelines that recommend the use of fondaparinux under various conditions. This paper aims to review the recent data and the subsequent updates in the recommendations of various guidelines on the use of fondaparinux sodium.
Mots clés
Texte intégral:
Disponible
Collection:
Bases de données internationales
Base de données:
MEDLINE
Sujet Principal:
Thrombose
/
Thrombose veineuse
/
COVID-19
Type d'étude:
Étude pronostique
Les sujets:
Vaccins
Limites du sujet:
Femelle
/
Humains
/
Grossesse
langue:
Anglais
Revue:
J Cardiovasc Pharmacol Ther
Thème du journal:
Maladies vasculaires
/
Cardiologie
/
Pharmacologie
Année:
2023
Type de document:
Article
Pays d'affiliation:
10742484221145010
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS